Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Principal Investigator
Study Number
NRG-GI004
Summary
This study is for individuals with colorectal cancer (CRC) known to have a genetic change (dMMR), has spread to other parts of your body, and has not yet received treatment. Individuals with this type of cancer are usually treated with combination therapy FOLFOX with bevacizumab (biologic drug). This study wants to learn if adding the experimental drug, atezolizumab with the usual treatment or giving the drug alone is more effective than the usual treatment alone. To be better than the usual treatment, atezolizumab given alone or with FOLFOX and bevacizumab should keep your cancer from growing for more than 7 months.
Phase
III
Contact
Available at the following location(s)
- Lebanon
- St. Johnsbury, VT
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms